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Summary  BK  and  JC  polyomaviruses  (PyV)  have  been  demonstrated  to  be  asso-
ciated  with  the  pathogenesis  of  various  human  cancers.  We  aimed  to  investigate
the  impact  of  BK  and  JC  polyomavirus  infections  on  several  clinical  parameters  in
different  human  cancers.  A  total  of  150  cancer  patients  were  included  in  the  study
(51  patients  with  solid  tumors,  48  patients  with  lymphomas  and  51  patients  with
leukemias).  Ampliﬁcation  of  PyV  DNA  was  performed  using  a  semi-nested  version
of  Polymerase  chain  reaction  targeting  the  T  genomic  region  of  PyV.  The  poly-
omavirus  load  was  determined  using  real-time  PCR  assay.  The  clinical  data  were
collected.  Polyomavirus  DNA  could  be  detected  in  84  (56%)  of  150  of  all  cancer-
ous  patients.  The  solid  tumors  had  the  lowest  proportion  of  JCV  (6  (11.8%)  of  51),
whereas  had  the  highest  proportion  of  JCV  (200  copies/l).  JCV  was  more  frequent
among  NHL  patients  (30%)  and  absent  in  HL  patients  (0%).  During  follow-up,  PyV
positivity  decreased  signiﬁcantly  (p  =  0.004)  in  lymphoma  patients  (n  =  28).  Although
PyV  positivity  decreased  signiﬁcantly  from  39%  to  7%  in  28  of  48  lymphoma  patients
after  treatment,  it  signiﬁcantly  persisted  in  leukemic  patients  after  treatment
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as  more  frequent  among  leukemic  patients  with  leukopenia.
mavirus  was  more  frequent  among  leukemic  patients  without
 their  overall  survival.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
ed.
I
T
t
e
5
T
v
o
u
t
d
t
s
d
c
p
s
9
[
J
i
h
l
c
i
t
t
o
l
t
a
l
s
w
r
f
w
t
p
T
p
p
e
m
w
a
c
c
p
H
i
c
r
p
a
p
P
S
T
h
l
l
H
s
t
c
2
m
s
m
l
w
H
N
O
c
v
follows: patients  diagnosed  with  acute  leukemia
(ALL or  AML),  lymphoma  (NHL  or  HD),  or  solid
tumors; age  ≥18  years  with  no  previous  treatment(from  22%  to  38%).  JC  w
The  presence  of  JC  polyo
any  signiﬁcant  impact  on
©  2016  King  Saud  Bin  Ab
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ntroduction
he  human  polyomaviruses  (HPyVs)  are  members  of
he polyomaviridae  family.  These  viruses  are  non-
nveloped  viruses,  ranging  in  size  from  45  nm  to
5 nm,  circular  and  double-stranded  DNA  genome.
he best-known  HPyVs  are  the  BK  virus  (BKV)  and  JC
irus (JCV),  which  share  75%  of  the  genomic  homol-
gy [1].  The  human  BKV  and  JCV  polyomaviruses  are
biquitous  viral  agents  that  infect  a  large  propor-
ion of  healthy  individuals.  Primary  infections  occur
uring childhood  and  are  usually  latent;  however,
he viruses  establish  latent  infections  in  renal  tis-
ues and  B-lymphocytes,  and  polyomavirus-related
iseases  can  develop  under  conditions  of  severe
ellular immunosuppression,  such  as  organ  trans-
lantation  or  hematological  malignancies  [2]. Adult
eroprevalence  for  BKV  and  JCV  is  high:  more  than
0% of  the  adult  population  is  seropositive  for  BKV
3],  whereas  50—80%  of  adults  have  antibodies  to
CV [4].
Reactivation  of  the  BK  virus  (BKV)  infection
s related  to  urinary  tract  diseases,  such  as
emorrhagic cystitis,  ureteric  stenosis,  glomeru-
onephritis,  and  graft  nephropathy,  which  are  most
ommonly  observed  in  transplant  patients  receiving
mmunosuppressive  therapy.  BKV  may  contribute
o allograft  dysfunction  in  up  to  8%  of  the  renal
ransplant patients,  resulting  in  graft  loss  in  45%
f these  cases  [5].  Reactivation  of  JC  virus  (JCV)  is
inked to  progressive  multifocal  leukoencephalopa-
hy (PML)  in  HIV-AIDS,  hematological  diseases
nd autoimmune  diseases  treated  with  certain
ymphocyte-speciﬁc  antibodies  [6].
Recently,  JCV  was  found  in  non-neural  cancers,
uch as  gastric  and  lung  cancers  [7].  JCV  infection
as ﬁrst  reported  as  a  potential  risk  factor  for  colo-
ectal cancer  (CRC)  by  Laghi  and  his  team  [8],  who
ound that  96%  of  colorectal  colon  (CRC)  tissues
ere positive  for  JCV  DNA  sequences  [7].
Hirsch described  ﬁve  different  pathology  pat-
erns  for  PyV  infections.  One  of  the  described
athology patterns  was  oncogenic  pathology  [9].
he different  types  of  polyomavirus  pathology  are
redicted  to  emerge  due  to  different  underlying
rocesses that  can  cause  severe  and  fatal  dis-
ases [9]. Accordingly,  increasing  or  high  viral  loads
n
s
iust  be  relevant  markers  in  entities  associated
ith high-level  replication,  such  as  polyomavirus-
ssociated nephropathy,  PML  and  hemorrhagic
ystitis.
Several studies  have  shown  that  polymerase
hain reaction  is  an  effective  tool  for  detecting
olyomaviruses  in  a  range  of clinical  samples  [10].
owever, few  records  in  the  literature  address  the
mpact of  PyV  infection  on  the  pathogenesis  of  can-
er diseases.
Therefore,  we  aimed  to  investigate  the  cor-
elation between  the  presence  of  BK  and  JC
olyomavirus infections  and  clinical  parameters
nd its  association  with  the  overall  survival  in
atients  with  various  human  cancers.
atients and methods
tudy population
his  prospective  study  included  99  patients  with
ematological  malignancies  (acute  leukemia  (acute
ymphocytic  ALL  and  acute  myeloid  AML)  and
ymphoma  (Hodgkin’s  lymphoma  (HL)  and  Non-
odgkin’s  lymphoma  (NHL))  and  51  patients  with
olid tumors  who  were  diagnosed  and  treated  at
he Medical  Oncology  Department,  National  Can-
er Institute  (NCI),  Cairo  University.  Additionally,
0 apparently  healthy  normal  individuals  served  as
atched controls.  The  patients  were  enrolled  in  the
tudy between  2010  and  2012.  All  of  the  experi-
ents were  performed  in  compliance  with  relevant
aws and  institutional  guidelines  and  in  accordance
ith the  ethical  standards  of  the  Declaration  of
elsinki.  The  Institutional  Review  Board  (IRB)  of  the
CI approved  the  protocol,  IRB  No.  IRB00004025,
rganization  No.  IORG0003381.  Informed  written
onsent  was  obtained  from  all  patients  and  indi-
iduals  enrolled  in  the  study.
The inclusion  criteria  for  the  study  were  asor antiviral  treatment.  All  of  the  patients  were
ubjected  to  a pretreatment  assessment,  includ-
ng complete  history  and  physical  examination,  as
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well  as  routine  baseline  investigations  required
for diagnosis  and  staging  according  to  each  dis-
ease category  using  the  WHO  criteria  for  diagnosing
hematological malignancies  and  the  AJCC-UICC
2010 for  solid  tumors.
Methods
Specimen  collection
Serum  samples  were  obtained  from  each  patient
with hematological  malignancy  before  and  after
treatment,  from  patients  with  solid  tumors,  as  well
as from  controls.  The  serum  samples  were  stored  in
aliquots at  −20 ◦C  until  processed.
Molecular  detection
Nucleic  acid  extraction.  A  DNA  sample  was
extracted using  the  QIA  amp  viral  RNA  extraction  kit
(Clinilab, Qiagen,  Hilden,  Germany).  The  extraction
was performed  according  to  the  manufacturer’s
instructions.  The  amount  of  viral  DNA  was  mea-
sured  using  spectrophotometry  and  a  Nano-Drop
2000 spectrophotometer  (Thermo  Scientiﬁc/US,
Canada), and  100  ng  of  DNA  template  was  used  in
the PCR  assays.  The  DNA  extracts  were  placed  on
ice, were  used  immediately  for  PCR  and  were  sub-
sequently  stored  at  −80 ◦C  until  additional  analysis
was performed.
Detection  of  BK-JC  polyomaviruses.  The  samples
were subjected  to  a  semi-nested  version  of  PCR
(sn-PCR)  targeting  large  T  genomic  region  of  JC
polyomavirus.  During  the  ﬁrst  ampliﬁcation,  both
BK-JC viruses  were  ampliﬁed  using  the  common
primers (BKJC1,  BKJC2)  targeting  the  nucleotides
position from  4391  to  4566  of  the  BKV  genome
(Accession NC  001538)  and  the  nucleotides  position
from 3978  to  4150  of  the  JCV  genome  (Accession
AF281613). The  ampliﬁcation  was  conducted  in  a
ﬁnal volume  of  25  l  of  5-Prime  Master  Mix  (Berlin,
Germany) containing  0.2  M  of  outer  primers  using
the following  thermal  cycle  program  (Perkin-Elmer
Cetus), according  to  previously  published  proto-
cols  [11—13].  The  polyomaviral  DNA  concentration
was measured  using  spectrophotometry  and  a  Nano-
Drop 2000  spectrophotometer,  and  100  ng  of  DNA
template  was  used  in  the  PCR  assays.  BK  poly-
omavirus VR-837  (ATCC-USA)  and  JC  polyomavirus
VR-1583(ATCC-USA)  were  extracted  using  the  same
extraction  procedure  for  the  samples.  Polyomavirus
positive and  negative  (water)  controls  were  run  in
each PCR  assay.
In the  second  ampliﬁcation,  semi-nested  PCR
(sn-PCR)  primers  targeting  the  nucleotides  posi-
tion from  4391  to  4539  of  the  BKV  genome  and
the nucleotides  position  from  3978  to  4048  of  the
JCV genome  [12]  were  used,  as  explained  in  our
t
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revious  report  on  solid  tumor  patients  by  the  same
eam [11].
etection  of  ampliﬁed  product  by  agarose  gel
lectrophoresis.  Fifteen  microliters  of  the  PCR
roduct  was  subjected  to  electrophoresis  on  a  2.5%
garose gel  (Sigma)  in  Tris—acetate  buffer  (TAE
X) pH  8.2,  stained  with  0.5  g/ml  ethidium  bro-
ide and  examined  under  UV  transillumination  and
hotographed.  The  product  sizes  were  estimated
y comparing  with  100  bp  DNA  ladder  (Amersham,
K). The  ampliﬁed  fragments  were  148  bp  for  BKV
nd 71  bp  for  JCV  [11].
ensitivity  and  speciﬁcity  of  snPCR  assay
he snPCR  assay  was  subjected  to  sensitivity  and
peciﬁcity  assays,  as  described  in  a previously  pub-
ished report  [11].
etection  of  PyV  by  quantitative  real  time  PCR
he detection  and  quantiﬁcation  of  PyV  viral  load
ere performed  using  real-time  detection  system
Applied  Biosystems  Step  One  TM  Real  Time  PCR
ystem  Thermal  Cycling  Block,  Singapore)  [11].
tatistical analysis
he  data  were  analyzed  using  IBM  SPSS  advanced
tatistics version  20  (SPSS  Inc.,  Chicago,  IL,  USA).
he chi-square  test  or  Fisher’s  exact  test  was  used
o examine  the  relationship  between  the  qualita-
ive variables.  McNemar  test  was  used  to  compare
he qualitative  variables  before  and  after  treat-
ent.  For  the  not  normally  distributed  quantitative
ata, a comparison  between  the  two  groups  was
erformed  using  Mann—Whitney  test.  The  com-
arison between  the  three  groups  was  performed
sing Kruskal—Wallis  test,  and  subsequently  post
oc Scheffe  test  was  used  for  pair-wise  comparison
ased on  Kruskal—Wallis  distribution.  Survival  anal-
sis was  performed  using  Kaplan—Meier  method,
nd a  comparison  between  two  survival  curves  was
onducted  using  log-rank  test.  Hazard  ratio  (HR)
ith its  95%  conﬁdence  interval  (CI)  was  calculated
sing Cox  proportional  hazard  model  for  univariate
nd multivariate  analyses.  All  of  the  tests  are  two-
ailed. A  p  <  0.05  was  considered  to  be  statistically
igniﬁcant.
esults
he  current  study  included  51  patients  with  solid
umors, 51  patients  with  acute  leukemia,  and  48
atients with  lymphoma.  The  median  age  for  the
ntire group  was  41  years  (range,  18—77  years)  with
 male/female  ratio  of  approximately  1.1:1.  The
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Table  1  Clinical  and  laboratory  characteristics  in  studied  cancer  patients  before  starting  of  treatment.
Leukemias
n  =  51
Lymphomas
n =  48
Solid  tumors
n  =  51
p  value
Age  (yrs)  31  (18—56)  45(18—73)  49  (22—77)  <0.001
Sex
0.012
Males  30(58.8)  30(62.5)  18(35.3)
Females  21(41.2)  18(37.5)  33(64.7)
Male:Female  ratio 1.4:1  1.7:1  0.6:1
AST  (IU/L) 24.0(15—133) 26.0(11—183) 22(12—62) 0.062
ALT  (IU/L) 26.0(11—143) 24.5(9.0—159) 22(8—65) 0.103
T.Bil  (mg/dl)  0.8(0.3—4.1)  0.7(0.3—8.8)  0.5(0.2—3.7)  <0.001
Creatinine  (mg/dl)  0.8(0.35—2.4)  0.8(0.4—1.67)  0.8(0.4—3.1)  0.888
Hb  (g/dl)  8.1(2.5—13.0)  12.3(8.1—15.1)  12.0(7.3—15.4)  <0.001
TlC  (×109/l)  16.0(1.0—327)  6.6(2.7—20.4)  6.8(1.9—18.6)  <0.001
ANC  (×109/l)  3.35(0.011—165.143)  3.822(0.918—4.26)  3.96(0.190—2.401)  0.814
ALC  (×109/l)  3.22(0.213—178.340)  1.49  (0.664—7.140)  2.04(0.113—4.300)  <0.001
AMC  (×109/l)  0.58(0.011—229.95)  0.422(0.160—1.15)  0.408(0.100—2.23)  0.004
Platelets  (×109/l)  42.0(3.0—321.0)  241.5(106.0—699.0)  289.5(0.0—679.0)  <0.001
Data are presented as median (range) or No.(%), p value < 0.05 signiﬁcant. AST: Aspartate aminotransferase, ALT: Alanine amino-
transferase, T. Bil: Total bilirubin, Hb: Hemoglobin concentration, TLC: Total leukocytic count, ANC: Absolute neutrophilic count,
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iALC: Absolute lymphocytic count, AMC: Absolute monocytic 
g/dl: gram/deciliter, l: liter.
emographic,  clinical  and  laboratory  characteris-
ics are  summarized  in  Table  1.
The  patients  with  acute  leukemia  were  younger
ompared to  the  remaining  patients,  whereas  those
ith solid  tumors  were  older.  The  females  were
ominant in  the  solid  tumors  category;  in  con-
rast, more  males  had  hematological  malignancies.
he most  common  solid  tumor  was  breast  followed
y hepatocellular  carcinoma  (HCC)  and  colorec-
al cancers;  NHL  and  AML  were  the  most  common
ematological malignancies.
isease outcome
n  solid  tumors,  70.6%  of  the  patients  achieved
bjective response  (complete  and  partial),  and
n hematological  malignancies,  approximately  50%
f the  patients  had  complete  or  partial  response
nd the  remaining  patients  had  stable  or  pro-
ressive disease.  During  the  last  follow-up,  the
ighest  mortality  rate  was  found  in  leukemic
atients representing  72.5%  followed  by  patients
ith lymphoma  and  solid  tumors  (56.2%  and  21.5%,
espectively).
resence of BK and JC polyomavirus
nfections  in all studied groups
orty-two  (28%)  of  150  patients  were  positive  for
K polyomavirus  DNA  (BKV)  and  33  (22%)  of  150
atients  were  positive  for  JC  polyomavirus  DNA
JCV)  as  detected  by  a  semi-nested  version  of
he PCR  assay.  Seven  (17.6%)  of  51  patients  with
h
D
P, IU/L: international unite/liter, mg/dl: milligram/deciliter,
olid  tumors  were  positive  for  polyomavirus  DNA
ut were  not  positive  for  BKV  or  JCV.  No  patient
n the  healthy  control  group  showed  presence  of
olyomavirus  (BKV  or  JC)  infections.  There  was  no
igniﬁcant  difference  in  the  proportion  of  poly-
maviruses  (total  positive  BK  or  JC  as  detected
y the  ﬁrst-round  PCR  assay)  among  the  different
ypes of  cancers;  the  viruses  were  detected  in  28
55%) of  51  patients  with  solid  tumors,  26  (54%)
f 48  patients  with  lymphomas  and  30  (59%)  of  51
atients with  leukemias  (p  = 0.880)  (Table  2).  How-
ver, JCV  was  apparently  less  frequent  in  patients
ith solid  tumors  (p  =  0.058).  The  median  viral  load
as apparently  higher  in  patients  with  solid  tumors
ompared  to  those  with  hematological  malignan-
ies with  a  trend  toward  statistical  signiﬁcance
p =  0.067)  (Table  2).
Among the  patients  with  lymphoma,  there  was
o signiﬁcant  difference  in  the  distribution  of  BKV
etween  HL  and  NHL  patients  (p  =  0.58).  JCV  DNA
as detected  in  30%  of  NHL  patients  compared  to
one of  the  HL  patients  (p  =  0.074).  In  leukemic
atients, there  was  no  signiﬁcant  difference  in  the
istribution  of  BKV  and  JCV  among  both  AML  and
LL subtypes  (p  = 0.941,  and  0.579,  respectively)
Table  3).
resence of BK  and JC polyomavirus
nfections  in follow-up patients with
ematological malignancy
uring  the  follow-up,  the  number  of  patients  with
yV DNA  was  no  more  detected  after  treatment
26  S.A.  Loutfy  et  al.
Table  2  Distribution  of  polyomaviruses  as  detected  by  PCR  among  studied  cancer  patients.
PyV  results  Leukemias
n  =  51
Lymphomas
n =  48
Solid  tumors
n  =  51
p value
PyV  19(37.3)  14(29.2)  17(33.3)  0.761
BKV  15(29.5)  14(29.2)  13(25.5)  0.862
JCV  15(29.5)  12(25.0)  6(11.8)  0.058
Total  positives 30(59)  26(54.2)  28(55)  0.880
Quantitative  PyV,  n  (viral  load) n =  18 n =  14 n =  23
0.067Median  (Range)  copies/l 91.5(10—2000) 20(10—100) 200(10—85  ×  106)
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aData are presented as No. (%) or median (range). p value < 0.0
PyV: Polyomavirus (as detected by 1st round PCR assay), BKV: 
from  39%  to  7%  in  28  of  48  lymphoma  patients
(p = 0.004).  There  were  no  signiﬁcant  changes
in polyomavirus  BK  and  JC  infections  in  acute
leukemic patients,  whereas  BK  polyomavirus  infec-
tion (as  performed  using  the  semi-nested  PCR  assay)
was increased  after  treatment  (p  =  0.031)  (Table
S1).
Presence of BK and JC polyomavirus DNA
and its association with biochemical and
hematological parameters in all studied
cancer patients
Regarding  the  analysis  of  hematological  parame-
ters,  our  results  showed  that  the  presence  of  BK
polyomavirus  infection  was  signiﬁcantly  associated
with  a  decrease  in  the  TLC  count  among  patients
with solid  tumors  (p  =  0.025),  whereas  the  presence
of JC  polyomavirus  was  associated  with  ALC  in  the
same group  of  patients  (p  =  0.021).  Such  ﬁndings
were not  observed  in  patients  with  hematological
malignancy  or  in  the  follow-up  groups.
In  the  analysis  of  the  presence  of  polyomaviruses
(BK and  JC),  the  results  showed  that  the  percent-
age of  JC  polyomavirus  among  leukemic  patients
p
r
(
i
Table  3  Distribution  of  polyomaviruses  as  detected  by  PC
patients.
PyV  results  Lymphomas
n  =  48
HL
n  =  8
NHL
n  =  40
BKV  3(38)  11(28)  
JCV  0(0)  12  (30)  
Total  positives  3(38)  23(58)  
Quantitative  PyV,  n  1  13
(Viral  load)  Median  (Range)
copies/l
10(10)  20(10—100)  
Data are presented as No.(%) or median (range). p value < 0.05 sign
PyV: Polyomavirus, BKV: BK-virus, JCV: John Cunningham, HL: Hodg
myeloid leukemia, ALL: Acute lymphoblastic leukemia.iﬁcant.
rus, JCV: John Cunningham virus.
ith  TLC  <4  ×  109 was  signiﬁcantly  higher  than  in
he patients  with  a higher  count  (TLC  >4  ×  109).
his ﬁnding  was  also  observed  in  the  same  group
f patients  with  ANC  <1500,  where  the  percentage
f patients  with  JC  polyomavirus  was  border-line
igniﬁcantly higher  than  in  patients  with  a higher
ount (ANC  >1500)  and  p  was  0.06.  Table  S2  showed
o signiﬁcant  correlation  between  the  presence  of
olyomaviruses  and  abnormal  values  of  several  bio-
hemical  parameters  in  patients  with  solid  tumor
ancers.  We  observed  the  same  ﬁndings  among
ollow-up patients  with  hematological  malignancy.
K and JC polyomavirus DNA and outcome
f disease
n  persons  with  solid  tumors,  14  patients  relapsed,
hereas 11  patients  died  by  the  end  of  the  study.  Six
42.9%) of  the  relapsed  patients  were  positive  for
yV DNA,  and  ﬁve  (45%)  of  the  patients  who  died
lso demonstrated  positive  results.  Half  of  the  22
atients with  relapsed  lymphoma  showed  a  positive
eaction  to  polyomavirus  (7  BKV  and  4 JCV)  and  nine
45%) of  the  patients  who  died  demonstrated  pos-
tive results  (5  BKV  and  4  JCV).  Of  the  26  patients
R  among  different  types  of  hematological  malignancy
p  value  Leukemias
n  =  51
p value
AML
n =  31
ALL
n =  20
0.58  9  (29)  6  (30)  0.941
0.074  10  (32)  5  (25)  0.579
0.442  19(61)  11(55)  0.656
— 11 7 0.72483(33—2000)  100(10—250)
iﬁcant.
kin’s lymphoma, NHL: Non-Hodgkin’s lymphoma, AML: Acute
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limit [18]; other  factors  related  to  host  genetics
[19]; and  other  sites  of viral  latency  [20].igure  1  Relation  of  overall  survival  with  age  in  solid
umors.
ensored:  alive,  OS:  overall  survival
ith  relapsed  leukemia,  15  (57.7%)  patients  showed
ositive  results  (9  BKV  and  6  JCV),  as  well  as  nine
64.3%)  of  14  patients  who  died  (7  BKV  and  2  JCV).
K and JC polyomavirus infection and
verall survival (OS)
n  patients  with  solid  tumors,  younger  age  was  sig-
iﬁcantly  associated  with  superior  OS  compared
ith older  age  (p  =  0.027),  whereas  in  leukemic
atients, male  sex,  younger  age  and  initial  TLC
4 ×  109 were  factors  associated  with  signiﬁcantly
etter OS,  indicating  signiﬁcant  p  0.023,  0.007  and
.007, respectively.  Positivity  to  polyomavirus  had
o impact  on  OS  in  patients  with  solid  tumors
r leukemia  but  showed  a  trend  toward  signiﬁ-
ant better  OS  in  patients  with  lymphoma  (p  =  0.07)
Figs.  1—3  and  S1,S2).
iscussion
t  has  been  reported  that  seroprevalence  of  BKV
nd JCV  infections  in  adults  ranged  from  60%
o 100%  [14].  Moreover,  the  frequency  of  poly-
mavirus infections  was  found  to  occur  more
mong immunosuppressive  patients.  In  the  cur-
ent study,  our  analyses  revealed  the  following:
olyomavirus infections  were  detected  in  the  sera
f 56%  (84/150)  of  all  groups  of  immunocompro-
ised  cancer  patients;  JCV  infection  was  detected
n 22%  (33/150);  such  results  were  close  to  those
nalyses performed  on  colorectal  cancer  (CRC)
atients in  another  series  where  25  (18.2%)  of
37 patients  were  positive  for  JCV  infection  [15];
nother report  demonstrated  100%  positivity  of  JCV
F
L
Chomas  group.
ensored:  alive,  OS:  overall  survival
-antigen  among  patients  with  anal  carcinoma  [15].
ur results  demonstrated  that  the  number  of  can-
er patients  with  BKV  was  28%  but  was  15.6%  among
idney  transplant  patients,  which  indicates  that  the
requency  of BKV  infection  is  affected  by  the  type
f immunosuppressive  status  [16].
Regarding  healthy  individuals,  reports  have  indi-
ated that  the  positivity  rate  of  polyomaviruses
aries from  0%  to  94%  [17].  In the  present  study,
one of  our  apparently  healthy  individuals  showed
iremia  to  polyomaviruses  DNA  (0%).  Our  negative
esults  and  such  wide  variability  in  incidence,  as
eported  in  previous  studies,  may  be  attributed  to
he following  factors:  viral  load  beyond  detectionigure  3  Relation  of  overall  survival  with  age  in
eukemias  group.
ensored:  alive,  OS:  overall  survival
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In  the  present  study,  the  median  viral  load/ml  of
serum was  signiﬁcantly  higher  in  patients  with  solid
tumors than  those  with  hematological  malignan-
cies. Such  results  were  contrary  to  our  expectation
to ﬁnd  a  higher  viral  load  in  leukemic  patients  to
match  the  higher  frequency  of  JC  polyomavirus  pos-
itivity. Such  results  may  be  explained  as  follows:
1) Polyomaviruses  rely  on  cellular  enzymes  and
co-factors for  DNA  replication  and  these  pro-
teins are  expressed  in  S  phase.  Because  JCV
spreads by  replication  in  lymphoid  cells,  such
cells  are  not  affected  by  malignancy  and  func-
tion well  in  patients  with  solid  tumors,  which
is different  from  situations  with  hematological
malignancies  especially  in  leukemia.  Therefore,
the polyomavirus  infection  in  patients  with  solid
tumors  can  lead  to  lytic  infection  with  viral
ampliﬁcation [21].
2) Transient  effects  of  JCV  in  cellular  transfor-
mation, as  it  can  be  silenced  or  its  genome
lost during  cancer  progression  (‘‘hit  and  run’’
transformation mechanism),  explain  the  low
number  of  polyomavirus  positive  cells  in  tumors
[15].
3) Peripheral  blood  mononuclear  cells  are  the
second important  potential  site  of  BKV  latency
[22]  and  replication  for  JCV  [15].  Therefore,
additional  study  is  required  to  investigate
the presence  of  polyomavirus  BKV  and  JCV
in peripheral  blood  leukocytes  to  provide
accurate  seroprevalence  results,  which  may
be helpful  as  a  noninvasive  biomarker  for
polyomavirus-related  leukemia  diagnosis.
Environmental  factors  (co-carcinogenesis)  and
host factors  (immune  status)  modulate  pathogen-
esis.
In the  current  study,  monitoring  patients  with
hematological malignancies  revealed  that  the
number  of  lymphoma  patients  positive  for  PyV
decreased  signiﬁcantly  after  treatment  than  before
treatment  (p  =  0.004).  In  contrast,  the  number  of
leukemic patients  with  positive  BKV  increased  sig-
niﬁcantly after  treatment  (p  = 0.031).  These  results
could  be  attributed  to  many  reasons,  such  as  the
following:
1) Different  lines  of  chemotherapy  are  used  for
each disease.  In  managing  lymphoma,  the  ther-
apy was  mild  and  led  to  reconstitution  of  the
host’s cellular  immune  mechanism;  hence,  the
attack infected  the  cells,  whereas  the  therapy
for leukemia  induced  an  immunosuppressive  sta-
tus favoring  the  replication  of  BK  polyomavirus.
2) Impairment  of  function  of  T-helper  cells  in
leukemic patients  is  due  to  other  causes
t
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than  chemotherapy,  such  as  diabetes  melli-
tus or  other  infections.  These  factors  increase
immunosuppression  and  may  enable  viral  repli-
cation  [23].
)  Additional  analysis  of  hematological  parameters
showed that  the  patients  with  acute  leukemia
suffered from  a severe  immunosuppressive  con-
dition due  to  their  malignancy  compared  to
the patients  with  lymphoma,  as  evidenced  by
comparing  the  values  of  hematological  parame-
ters TLC  (<4  ×  109), ANC  (<1500),  ALC  (<1000)
between both  groups  (lymphoma  and  acute
leukemia), where  lymphoma  patients  recorded
9/28 (32%),  4/28  (14%),  and  6/28  (21%),  respec-
tively)  vs  20/37  (54%),  19/37  (51.7%),  and  18/37
(48.6%),  respectively,  in  leukemias.  This  ﬁnding
supports  the  correlation  between  the  sever-
ity of  disease  and  increased  susceptibility  to
polyomavirus  infection  [15]. This  outcome  was
consistent  with  our  results,  which  showed  an
association  between  BKV  positivity  with  lower
TLC among  patients  with  solid  tumors  and  the
presence  of  an  association  between  JCV  pos-
itivity with  lower  ALC  in  the  same  group  of
patients. Additionally,  our  results  showed  a  sig-
niﬁcantly  higher  percentage  of  JC  polyomavirus
among leukemic  patients  with  TLC  <4  ×  109 than
in patients  with  a higher  count  (TLC  >4  ×  109),
whereas  the  percentage  of  JCV  was  borderline
signiﬁcantly  high  in  the  same  group  of  patients
with ANC  <1500  than  in  patients  with  a  higher
count (ANC  >15,000)  (p  =  0.06).
Regarding  the  presence  of  polyomaviruses  and
tatus of  disease,  our  results  showed  a  higher
ercentage of  polyomaviruses  among  relapsed  can-
erous patients  (6  (42.9%)  of  14  patients  with  solid
umors, 11  (50%)  of  22  patients  with  lymphomas,
nd 15  (58%)  of  26  patients  with  leukemias).
his result  could  be  another  evidence  for  the
resence of  polyomavirus  infection  and  its  asso-
iation  with  immunosuppression  status  of  the
isease.
Those patients  are  at  higher  risk  of  severe
olyomavirus-associated  diseases  and  should  be
arefully monitored  using  appropriate  management
hroughout their  course  of  cancer  treatment.
Regarding  the  patients  who  died  and  were  pos-
tive for  polyomaviruses,  a  higher  percentage  of
olyomavirus  DNA  was  among  the  leukemic  patients
ho died  (9  (64%)  of  14  patients  vs.  5  (45%)  of
1 patients,  and  9  (45%)  of  20  patients  with  solid
umors and  lymphomas,  respectively).  This  obser-
ation  indicates  a  double  hit  from  treatment  for
eukemia  disease  and  a  pathogenetic  effect  due  to
iral infection.
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[2] Brodano GB, Sabbioni S, Martini F, Negrini M, Corallini A,
Tognon M. BK virus, JC virus and Simian virus 40 infectionsPresence  of  BK&JC  polyomaviruses  in  different  can
In  the  current  study,  all  of  the  studied  cancer
atients were  subjected  to  a  one-year  overall  sur-
ival analysis  to  investigate  the  impact  of  several
igniﬁcant parameters  on  the  survival  of  our  cancer-
us patients.  Our  results  revealed  that  age  showed
 signiﬁcant  impact  on  the  overall  survival  of
atients with  solid  tumors.  This  ﬁnding  is  matched
ith what  is  known  about  aging  and  its  impact
n efﬁciency  of  T-cell  effector  functions,  such  as
ytotoxicity  or  B-cell  help  in  immunocompetent
ndividuals.  The  decreased  antibody  production  and
 shortened  immunological  memory  are  the  conse-
uences  [24].  In  cancer  patients,  aging  may  cause
dditional  suppression  of  T  cells  and  PMNL  [25],
eading to  an  increased  susceptibility  to  infectious
iseases.
This ﬁnding  was  also  observed  in  our  leukemic
atients where  young  age,  initial  low  count  of  TLC
n addition  to  male  gender  increased  the  overall
urvival of  such  patients.  However,  the  presence
f polyomavirus  infection  did  not  show  an  impact
n overall  survival.  Our  results  showed  that  a bor-
erline trend  toward  increasing  the  overall  survival
n the  presence  of  PyV  is  contrary  to  our  expec-
ation and  is difﬁcult  to  explain  because  we  could
ot ﬁnd  a  mechanism  by  which  PyV  improves  over-
ll survival  except  that  the  suggestion  regarding
he presence  of  PyV  replication  in  B  cells  of  NHL
ymphoma patients  could  act  as  a  stimulus  for  B
ymphocyte  proliferation  and,  hence,  is  associated
ith increasing  levels  of  antibody;  this  ﬁnding  could
uggest an  etiological  role  of  PyV  in  NHL  [26].
herefore,  it  would  be  useful  to  examine  the  cel-
ular immune  responses  against  PyV  replication  and
valuate whether  this  result  would  clinically  affect
he outcome  of  cancer.  Furthermore,  the  sequenc-
ng analysis  of  PyV  in  positive  patients  is  necessary
o clarify  whether  it  is viral  reactivation  or  reinfec-
ion.
onclusions
he  presence  of  JC  polyomavirus  was  more  frequent
mong patients  with  acute  leukemia.  Addition-
lly, positivity  of  BK  polyomavirus  increased  after
reatment  in  the  same  group  of  patients.  The  pres-
nce of  BK  and  JC  polyomavirus  infections  did  not
eveal a  signiﬁcant  impact  on  the  overall  survival
n leukemic  patients  but  exhibited  a  trend  toward
mprovement in  the  overall  survival  in  lymphoma
atients (0.069).  An  additional  larger-scale  study
s required  to  explain  such  observations  and  may
rovide  evidence  concerning  the  likely  role  of  PyV
n the  etiology  of  lymphoma.patients  29
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